Skip to main content

Anne C. Goldberg, MD, FNLA, FACP, FAHA

Anne C. Goldberg, MD, FNLA, FACP, FAHA

Professor of Medicine

Division of Endocrinology, Metabolism & Lipid Research

Washington University in St. Louis

St. Louis, MO

From the perspective of a lipid medicine specialist, how do the results of the now-published ODYSSEY Outcomes Trial, and related trials, help you select patients for PCSK9-mediated LDL-C reduction? And what targets do you advocate?

From the perspective of a lipid medicine specialist, how do the results of the now-published ODYSSEY Outcomes Trial, and related trials, help you select patients for PCSK9-mediated LDL-C reduction? And what targets do you advocate?

Anne C. Goldberg, MD, FNLA, FACP, FAHA

From a lipid specialist perspective, how do you navigate the risk territory of LDL-C levels <70 mg/dL with PCSK9 inhibitors? And in which patient subgroups do these agents offer unique outcome-related benefits?

From a lipid specialist perspective, how do you navigate the risk territory of LDL-C levels <70 mg/dL with PCSK9 inhibitors? And in which patient subgroups do these agents offer unique outcome-related benefits?

Anne C. Goldberg, MD, FNLA, FACP, FAHA

What are the specific patient types that you manage in your lipid-focused practice and which are referred to you for potential intervention with a PCSK9 inhibitor? Why are these patients being referred to you for PCSK9-mediated LDL-C reduction?

What are the specific patient types that you manage in your lipid-focused practice and which are referred to you for potential intervention with a PCSK9 inhibitor? Why are these patients being referred to you for PCSK9-mediated LDL-C reduction?

Anne C. Goldberg, MD, FNLA, FACP, FAHA

Why are patients who should clearly be on a PCSK9 inhibitor not being treated in the primary cardiology setting, but rather seeking and obtaining this treatment in the lipid clinic environment?

Why are patients who should clearly be on a PCSK9 inhibitor not being treated in the primary cardiology setting, but rather seeking and obtaining this treatment in the lipid clinic environment?

Anne C. Goldberg, MD, FNLA, FACP, FAHA

To what degree have you observed statin intolerance or resistance in patients with high risk CAD? What protocol do you employ to mitigate and/or manage statin intolerance? Where does the PCSK9 inhibitor fit into your sequencing strategy?

To what degree have you observed statin intolerance or resistance in patients with high risk CAD? What protocol do you employ to mitigate and/or manage statin intolerance? Where does the PCSK9 inhibitor fit into your sequencing strategy?

Anne C. Goldberg, MD, FNLA, FACP, FAHA

When is 70 mg/dL not good enough? Is this a threshold? What clinical factors suggest lower targets are better? What is happening at the vascular biology level?

When is 70 mg/dL not good enough? Is this a threshold? What clinical factors suggest lower targets are better? What is happening at the vascular biology level?

Anne C. Goldberg, MD, FNLA, FACP, FAHA

In the lipid clinic setting, in patients you have treated with PCSK9 inhibitors, what are you finding as far as regimen adherence, toleration, and patient engagement/satisfaction with these injectable strategies?

In the lipid clinic setting, in patients you have treated with PCSK9 inhibitors, what are you finding as far as regimen adherence, toleration, and patient engagement/satisfaction with these injectable strategies?

Anne C. Goldberg, MD, FNLA, FACP, FAHA

Which patients, in your view, are not candidates for PCSK9 inhibition?

Which patients, in your view, are not candidates for PCSK9 inhibition?

Anne C. Goldberg, MD, FNLA, FACP, FAHA

How should the lipid specialist approach the individual with diabetes who doesn’t yet have ASCVD?

How should the lipid specialist approach the individual with diabetes who doesn’t yet have ASCVD?

Anne C. Goldberg, MD, FNLA, FACP, FAHA